Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) - Evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins

European Journal of Endocrinology

Volumn 135, Issue 4, 1996, Pages 425-432

  Vaag, Allan A ^a   Holst, Jens J ^b   Vølund, Aage ^c   Beck Nielsen, Henning ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE TOLERANCE; HUMAN; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TWIN DISCORDANCE;

EID: 0029856880     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1350425     Document Type: Article

References (29)

1. La Barre J. Sur les possibilities d'un traitment du diabetes par l'incretine. Bull Acad R Med Belg 1932;12:620-34
2. Elrick H, Stimmler L, Hlad Jr CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol 1964;24:1076-82
3. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;2:20-1
4. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev 1988;9:122-34
5. Krarup T, Groop P-H. Physiology and pathophysiology of GIP: a review. Scand J Clin Lab Invest 1991;51:571-9
6. Lund PK, Goodman RH, Dee PC, Habener JF. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci USA 1982;79: 345-9
7. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983;302:716-18
8. Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992;35:701-11
9. Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for NIDDM. J Clin Invest 1995;95: 690-8
10. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52
11. Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991;87:415-23
12. Orskov C, Rabenhoj L, Kofod H, Wettergren A, Holst JJ. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994;43:535-9
13. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-7
14. Holst JJ, Bersani M. Assays for peptide products of somatostatin gene expression. In: Methods of neurosciences New York: Academic Press, 1991: 3-22
15. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, et al. Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type 1 (insulin dependent) diabetics. J Clin Endocrinol Metab 1983;56:1306-12
16. Moody AJ, Jörgensen KD, Thim L. Structure-function relationships in porcine GIP [abstract]. Diabetologia 1981;21:306
17. Moody AJ, Krarup T, Larsen KL. Reactivity of anti-porcine gastric inhibitory polypeptide (GIP) rabbit antiserum R65 with synthetic human and porcine GIP. Scand J Clin Lab Invest 1992;52:103-6
18. Krarup T, Holst JJ, Larsen KL. Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat. Am J Physiol 1985;12:E195-200
19. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610-30
20. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993;361:362-5
21. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91: 301-7
22. Boyns DR, Crosseley JN, Abrams ME, Jarrett RJ, Keen H. Oral glucose tolerance and related factors in a normal population sample. Blood sugar, plasma insulin, glyceride, cholesterol measurements and the effect of age and sex. Br Med J 1969;1:595-8
23. Wellborn TA, Stenhouse NS, Johnstone CG. Factors determining serum-insulin response in a population sample. Diabetologia 1969;5:263-6
24. Ferrara A, Wingard DL, Barrett-Conner E, Edelstein SL. Sex differences in insulin levels in older adults and the effect of body size, estrogen replacement therapy, and glucose tolerance status. Diabetes Care 1995;18(2):220-5
25. Roust LR, Stesin M, Go VL, O'Brien PC, Rizza RA, Service FJ. Role of gastric inhibitory polypeptide in postprandial hyperinsulinemia of obesity. Am J Physiol 1988;254:E767-74
26. McConnell JG, Alam MJ, O'Hare MMT, Buchanan KD, Stout RW. The effect of age and sex on the response of enteropancreatic polypeptides to oral glucose. Age Ageing 1983;12:54-62
27. Wedmann B, Schmidt G, Wegener M, Coenen C, Ricken D, Althoff J. Effects of age and gender on fat-induced gallbladder contraction and gastric emptying of a caloric liquid meal: a sonographic study. Am J Gastroenterol 1991;86:1765-70
28. Tucci A, Corinaldesi R, Stanghellini V, Tosetti C, Di Febo G, Paparo GF, et al. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology 1992;103:768-74
29. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73